Skip to Main Content

Paper Details

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
J Hematol Oncol
12
2022
Author NameAffiliation
Qingyi WeiThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2